<--- Back to Details
First PageDocument Content
Hepatocellular carcinoma / TheraSphere / Selective internal radiation therapy / Cholangiocarcinoma / Response Evaluation Criteria in Solid Tumors / Interventional radiology / SIR-Spheres / Neuroendocrine tumor / Radiation therapy / Medicine / Radiation oncology / Hepatology
Date: 2012-02-29 10:06:18
Hepatocellular carcinoma
TheraSphere
Selective internal radiation therapy
Cholangiocarcinoma
Response Evaluation Criteria in Solid Tumors
Interventional radiology
SIR-Spheres
Neuroendocrine tumor
Radiation therapy
Medicine
Radiation oncology
Hepatology

Research Reporting Standards for Radioembolization of Hepatic Malignancies

Add to Reading List

Source URL: www.sirweb.org

Download Document from Source Website

File Size: 436,70 KB

Share Document on Facebook

Similar Documents

Medicine / Cancer research / Clinical medicine / Response Evaluation Criteria in Solid Tumors / Health / PET Response Criteria in Solid Tumors / Immune-Related Response Criteria

Appendix N Response Evaluation Criteria in Solid Tumors (RECIST) The Response Evaluation Criteria in Solid Tumors (RECIST) were published in February 2000 by the European Organization for Research and Treatment of Cance

DocID: 1q9h6 - View Document

RTT / Brain tumor / Medical terminology / Medical physics / Cancer research / Response Evaluation Criteria in Solid Tumors / Imaging biomarker / Glioblastoma multiforme / Radiation therapy / Biomarker / Medical imaging / Progression-free survival

MayImproving Trial Success by Improving Tumor Assessment Jamal Gasmi, MD, PhD l Vice President & Global Leader Oncology & Hematology Drug Development, ICON Clinical Research James Conklin, MD, MS l Senior Vice Pre

DocID: 1pCHm - View Document

Clinical pharmacology / Antineoplastic drugs / Cancer treatments / Oncology / Cancer research / Response Evaluation Criteria in Solid Tumors / Chemotherapy / Clinical trial / Radiation therapy / Treatment of cancer / Adverse effect / Therapeutic index

Clinical Trial Template Instructions: This template has been created to assist in the development of investigator-initiated interventional clinical trials. Please note that it has two parts. The objective of Part 1 is

DocID: 1pCAL - View Document

Cancer treatments / Eli Lilly and Company / Platinum compounds / Benzamides / Gemcitabine / Organofluorides / Chemotherapy / Cisplatin / Response Evaluation Criteria in Solid Tumors / CHOP / Protein-bound paclitaxel / Pancreatic cancer

High complete and partial response rate in a phase Ib/II pilot trial with albumin-bound paclitaxel and gemcitabine plus cisplatin in patients with advanced pancreatic cancer Jameson GS1, Borazanci E1, Poplin E2, Barrett

DocID: 1osIl - View Document

Histopathology / End point of clinical trials / Response Evaluation Criteria in Solid Tumors / Vismodegib / Medicine / Basal-cell carcinoma / Carcinoma

Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma (BCC): 24-month update of the pivotal ERIVANCE BCC study A Sekulic,1 MR Migden,2 AE Oro,3 L Dirix,4 K Lewis,5 JD Hainsworth,6

DocID: 1gamh - View Document